Evidence map›Paper›PMID 29657904›Full record

ArticleCurrent surgery reports2017

Immunotherapy for Breast Cancer: Current and Future Strategies.

Austin D Williams, Kyle K Payne, Avery D Posey, Christine Hill, Jose Conejo-Garcia, Carl H June, Julia Tchou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current surgery reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Therapeutic vaccines for breast cancer: Has the time finally come?European journal of cancer (Oxford, England : 1990) · 2022
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.Archivum immunologiae et therapiae experimentalis · 2020
    Review
  18. Review
  19. Delivery technologies for cancer immunotherapy.Nature reviews. Drug discovery · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Austin D WilliamsDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, 10th floor South, Philadelphia, PA 19104, USA.
Kyle K PayneThe Wistar Institute, Philadelphia, PA, USA.
Avery D PoseyDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Christine HillDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Jose Conejo-GarciaDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Carl H JuneDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Julia TchouDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, 10th floor South, Philadelphia, PA 19104, USA.

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Project 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.P01CA214278 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARL H. JUNE · 2017 to 2026
$26.8M
NCI NIH HHS P01 CA214278NCI NIH HHS P30 CA010815
6 · The paper itself

Abstract

purpose of reviewThe breast tumor microenvironment is immunosuppressive and is increasingly recognized to play a significant role in tumorigenesis. A deeper understanding of normal and aberrant interactions between malignant and immune cells has allowed researchers to harness the immune system with novel immunotherapy strategies, many of which have shown promise in breast cancer. This review discusses the application of immunotherapy to the treatment of breast cancer. RECENT

findingsBoth basic science and clinical trial data are rapidly developing in the use of immunotherapy for breast cancer. The current clinical trial landscape includes therapeutic vaccines, immune checkpoint blockade, antibodies, cytokines, and adoptive cell therapy. SUMMARY: Despite early failures, the application of immunotherapeutic strategies to the treatment of breast cancer holds promise.

Indexed as

Breast cancerCancer vaccinesChimeric antigen receptor T cells (CAR T)Immune checkpointImmunotherapyOncolytic viruses

Identifiers

PMID29657904
PMCPMC5894864

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.